• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023

    11/1/23 4:05:49 PM ET
    $SCTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCTL alert in real time by email

    SAN DIEGO and GAINESVILLE, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO" or "Societal"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the third quarter 2023 after the market close on Wednesday, November 8, 2023. Societal's management team will host a webcast at 4:30 p.m. ET on that day to discuss the financial results and recent operational highlights.

    A live webcast can be accessed by visiting the "Investor Events" page in the Investor section of the company's website: https://ir.societalcdmo.com/events. In addition, an archived webcast will be available on the company's website approximately two hours after the event and will be available for 30 days.

    About Societal CDMO

    Societal CDMO (NASDAQ:SCTL) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

    In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Societal CDMO has the expertise to deliver on our clients' pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

    Societal CDMO: Bringing Science to Society. For more information about Societal CDMO's customer solutions, visit societalcdmo.com.



    Contacts:
    Stephanie Diaz (Investors)
    Vida Strategic Partners
    415-675-7401
    [email protected]
    
    Tim Brons (Media)
    Vida Strategic Partners
    415-675-7402
    [email protected]
    
    Ryan D. Lake (CFO)
    Societal CDMO
    770-531-8365
    [email protected]

    Primary Logo

    Get the next $SCTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCTL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCTL
    Financials

    Live finance-specific insights

    See more
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20

      4/8/24 4:05:23 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an

      4/8/24 10:10:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

      Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include

      11/14/22 6:45:00 AM ET
      $CING
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SCTL
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13D/A filed by Societal CDMO Inc. (Amendment)

      SC 13D/A - Societal CDMO, Inc. (0001588972) (Subject)

      4/9/24 4:15:44 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Societal CDMO Inc.

      SC 13G - Societal CDMO, Inc. (0001588972) (Subject)

      4/1/24 5:03:18 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Societal CDMO Inc.

      SC 13D - Societal CDMO, Inc. (0001588972) (Subject)

      3/6/24 5:11:25 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Societal CDMO Announces Appointment of Matt Arens to Board of Directors

      SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Matt Arens to the company's board of directors. Mr. Arens has more than 25 years of experience as a successful investment professional identifying innovative life science companies with high growth potential. For the past 15 years, he solely has managed dedicated health care portfolios. Mr. Arens currently serves as chief executive officer and senior po

      8/23/23 4:04:35 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Societal CDMO Appoints Elena Cant to Board of Directors

      SAN DIEGO and GAINESVILLE, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Elena Cant to the company's board of directors. Ms. Cant has more than 20 years of diverse business experience ranging across various functions including corporate development, business operations and strategy, marketing, commercial, manufacturing, and research and development. She has an impressive track record of establishing and growing functional groups,

      9/8/22 7:00:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Societal CDMO Inc.

      15-12G - Societal CDMO, Inc. (0001588972) (Filer)

      4/18/24 3:27:56 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Societal CDMO Inc.

      EFFECT - Societal CDMO, Inc. (0001588972) (Filer)

      4/12/24 12:15:06 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Societal CDMO Inc.

      EFFECT - Societal CDMO, Inc. (0001588972) (Filer)

      4/12/24 12:15:10 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20

      4/8/24 4:05:23 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an

      4/8/24 10:10:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.

      Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a definitive agreement with CoreRx, Inc. ("CoreRx") under which CoreR

      2/28/24 4:29:04 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arens Mathew Paul closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:37:26 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Weisman Wayne returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:36:07 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reasons Bryan M. returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:34:32 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care